Double Bond Pharmaceutical AB has started a scientific and technological collaboration with N. N. Alexandrov National Cancer Centre of Belarus

DBP and N. N. Alexandrov National Cancer Centre of Belarus will initiate the collaboration program immediately. The main goal for DBP is to get access to the knowledge and resources that are relevant to the development of DBPs front-line products - drugs SA-033 against liver cancer and Temodex against brain cancer - already from December 2016. "We are excited to be part of a long-term collaboration with N. N. Alexandrov National Cancer Centre of Belarus. This governmental organization can be a great resource and advisory board for the DBP within some clinical and technical